NCT01608867View on ClinicalTrials.gov

A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

June 30, 2017

Conditions
Solid Tumors
Interventions
BIOLOGICAL

OMP-54F28

dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks

Trial Locations (3)

48109

University of Michigan Health System, Ann Arbor

80045

University of Colorado Hospital, Aurora

85258

Pinnacle Oncology Hematology,, Scottsdale

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY